2oax: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Spirolactones are potent antagonists of the mineralocorticoid receptor, (MR), a ligand-induced transcription factor belonging to the nuclear, receptor superfamily. Spirolactones are synthetic molecules characterized, by having a C17 gamma-lactone, which is responsible for their antagonist, character. They harbor various substituents at several positions of the, steroid skeleton that modulate their potency in ways that remain to be, determined. This is particularly obvious for C7 substituents. The, instability of antagonist-MR complexes makes them difficult to, crystallize. We took advantage of the S810L activating mutation in MR, (MRS810L), which increases the stability of ligand-MR complexes, to, crystallize the ligand-binding domain (LBD) of MRS810L associated with, SC9420, a spirolactone with a C7 thioacetyl group. The crystal structure, makes it possible to identify the contacts between SC9420 and MR, and, elucidate the role of Met852 in the mode of accommodation of the C7, substituent of SC9420. The transactivation activities of MRS810L/Q776A, MRS810L/R817A and MRS810L/N770A reveal that the contacts between SC9420, and the Gln776 and Arg817 residues are crucial to maintaining MRS810L in, its active state, whereas the contact between SC9420 and the Asn770, residue only contributes to the high affinity of SC9420 for MR. Moreover, docking experiments with other C7-substituted spirolactones revealed that, the MRS810L-activating potency of spirolactones is linked to the ability, of their C7 substituent to be accommodated in LBD. Remarkably, the, MRS810L-activating and MRWT-inactivating potencies of the C7-substituted, spirolactones follow the same order, suggesting that the C7 substituent is, accommodated in the same way in MRS810L and MRWT. Thus, the MRS810L, structure may provide a powerful tool for designing new, more effective, MR antagonists.
Spirolactones are potent antagonists of the mineralocorticoid receptor (MR), a ligand-induced transcription factor belonging to the nuclear receptor superfamily. Spirolactones are synthetic molecules characterized by the presence of a C17 gamma-lactone, which is responsible for their antagonist character. They harbor various substituents at several positions of the steroid skeleton that modulate their potency in ways that remain to be determined. This is particularly obvious for C7 substituents. The instability of antagonist-MR complexes makes them difficult to crystallize. We took advantage of the S810L activating mutation in MR (MR(S810L)), which increases the stability of ligand-MR complexes to crystallize the ligand-binding domain (LBD) of MR(S810L) associated with 7alpha-acetylthio-17beta-hydroxy-3-oxopregn-4-en-21-carboxylic acid gamma-lactone (SC9420), a spirolactone with a C7 thioacetyl group. The crystal structure makes it possible to identify the contacts between SC9420 and MR and to elucidate the role of Met852 in the mode of accommodation of the C7 substituent of SC9420. The transactivation activities of MR(S810L/Q776A), MR(S810L/R817A), and MR(S810L/N770A) reveal that the contacts between SC9420 and the Gln776 and Arg817 residues are crucial to maintaining MR(S810L) in its active state, whereas the contact between SC9420 and the Asn770 residue contributes only to the high affinity of SC9420 for MR. Moreover, docking experiments with other C7-substituted spirolactones revealed that the MR(S810L)-activating potency of spirolactones is linked to the ability of their C7 substituent to be accommodated in LBD. It is remarkable that the MR(S810L)-activating and MR(WT)-inactivating potencies of the C7-substituted spirolactones follow the same order, suggesting that the C7 substituent is accommodated in the same way in MR(S810L) and MR(WT). Thus, the MR(S810L) structure may provide a powerful tool for designing new, more effective, MR antagonists.
 
==Disease==
Known diseases associated with this structure: Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600983 600983]], Pseudohypoaldosteronism type I, autosomal dominant OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600983 600983]]


==About this Structure==
==About this Structure==
Line 10: Line 13:


==Reference==
==Reference==
Structural Basis of Spirolactone Recognition by the Mineralocorticoid Receptor., Huyet J, Pinon GM, Fay MR, Fagart J, Rafestin-Oblin ME, Mol Pharmacol. 2007 Jun 14;. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17569793 17569793]
Structural basis of spirolactone recognition by the mineralocorticoid receptor., Huyet J, Pinon GM, Fay MR, Fagart J, Rafestin-Oblin ME, Mol Pharmacol. 2007 Sep;72(3):563-71. Epub 2007 Jun 14. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17569793 17569793]
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Fagart, J.]]
[[Category: Fagart, J.]]
[[Category: Fay, M.R.]]
[[Category: Fay, M R.]]
[[Category: Huyet, J.]]
[[Category: Huyet, J.]]
[[Category: Pinon, G.M.]]
[[Category: Pinon, G M.]]
[[Category: Rafestin-Oblin, M.E.]]
[[Category: Rafestin-Oblin, M E.]]
[[Category: SNL]]
[[Category: SNL]]
[[Category: aldosterone; steroid receptor; nuclear receptor; transcription factor; activating mutation]]
[[Category: aldosterone; steroid receptor; nuclear receptor; transcription factor; activating mutation]]
[[Category: hypertension; antagonist; spironolactone]]
[[Category: hypertension; antagonist; spironolactone]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 12:03:10 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:16:22 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA